Extracellular guanosine regulates extracellular adenosine levels

American Journal of Physiology - Cell Physiology

Volumn 304, Issue 5, 2013, Pages

  Jackson, Edwin K ^a   Cheng, Dongmei ^a   Jackson, Travis C ^a   Verrier, Jonathan D ^a   Gillespie, Delbert G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine; Adenosine 5' monophosphate; Guanosine; Guanosine 5' monophosphate; Purine nucleoside phosphorylase

Indexed keywords

ADENOSINE; ADENOSINE KINASE; ADENOSINE PHOSPHATE; CYCLIC GMP; CYTIDINE; CYTOSINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; GUANOSINE; GUANOSINE PHOSPHATE; PURINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE; URIDINE;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CELL MEMBRANE; DEPHOSPHORYLATION; ENDOTHELIUM CELL; LIMIT OF DETECTION; MESANGIUM CELL; NONHUMAN; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

ADENOSINE; ANIMALS; AORTA; CELLS, CULTURED; CORONARY VESSELS; ENDOTHELIAL CELLS; FIBROBLASTS; GUANOSINE; HUMANS; KIDNEY; MALE; MESANGIAL CELLS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; MYOCYTES, SMOOTH MUSCLE; PURINE-NUCLEOSIDE PHOSPHORYLASE; RATS; RATS, INBRED WKY;

EID: 84874589840     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00212.2012     Document Type: Article

References (100)

1. Ault-Riche DB, Lee Y, Yuan CS, Hasobe M, Wolfe MS, Borcherding DR, Borchardt RT. Effects of 4=-modified analogs of aristeromycin on the metabolism of S-adenosyl-L-homocysteine in murine L929 cells. Mol Pharmacol 43: 989-997, 1993.
2. Baker DC, Hanvey JC, Hawkins LD, Murphy J. Identification of the bioactive enantiomer of erythro-3-(adenin-9-yl)-2-nonanol (EHNA), a semi-tight binding inhibitor of adenosine deaminase. Biochem Pharmacol 30: 1159-1161, 1981.
3. Baldwin SA, Beal PR, Yao SYM, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflügers Arch 447: 735-743, 2004.
4. Barnes K, Dobrzynski H, Foppolo S, Beal PR, Ismat F, Scullion ER, Sun L, Tellez J, Ritzel MWL, Claycomb WC, Cass CE, Young JD, Billeter-Clark R, Boyett MR, Baldwin SA. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res 99: 510-519, 2006.
5. Bours MJL, Swennen ELR, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5=-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112: 358-404, 2006.
6. Casado FJ, Lostao MP, Aymerich I, Larrayoz IM, Duflot S, Rodriguez-Mulero S, Pastor-Anglada M. Nucleoside transporters in absorptive epithelia. J Physiol Biochem 58: 207-216, 2002.
7. Chan ESL, Cronstein BN. Adenosine in fibrosis. Mod Rheumatol 20: 114-122, 2010.
8. Cheng D, Ren J, Gillespie DG, Mi Z, Jackson EK. Regulation of 3=,5=-cAMP in preglomerular smooth muscle and endothelial cells from genetically-hypertensive rats. Hypertension 56: 1096-1101, 2010.
9. Chiang PK, Guranowski A, Segall JE. Irreversible inhibition of Sadenosylhomocysteine hydrolase by nucleoside analogs. Arch Biochem Biophys 207: 175-184, 1981.
10. Ciruela F, Saura C, Canela EI, Mallol J, Lluis C, Franco R. Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett 380: 219-223, 1996.
11. De Clercq E. S-adenosylhomocysteine hydrolase inhibitors as broadspectrum antiviral agents. Biochem Pharmacol 36: 2567-2575, 1987.
12. Deussen A, Lloyd HG, Schrader J. Contribution of S-adenosylhomocysteine to cardiac adenosine formation. J Mol Cell Cardiol 21: 773-782, 1989.
13. Deussen A, Pexa A, Loncar R, Stehr SN. Effects of homocysteine on vascular and tissue adenosine: a stake in homocysteine pathogenicity? Clin Chem Lab Med 43: 1007-1010, 2005.
14. Di Iorio P, Kleywegt S, Ciccarelli R, Traversa U, Andrew CM, Crocker CE, Werstiuk ES, Rathbone MP. Mechanisms of apoptosis induced by purine nucleosides in astrocytes. Glia 38: 179-190, 2002.
15. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A2B receptors. Circulation 96: 2656-2666, 1997.
16. Dubyak GR. Dueling nucleosides: regulation of extracellular adenosine by guanosine. Focus on "Extracellular guanosine regulates extracellular adenosine levels. " Am J Physiol Cell Physiol (January 16, 2013). doi: 10.1152/ajpcell.00012.2013.
17. Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology 111: 904-915, 2009.
18. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schonfeld C, Loffler M, Reyes G, Duszenko M, Karhausen J, Robinson A, Westerman KA, Coe IR, Colgan SP. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 202: 1493-1505, 2005.
19. Eltzschig HK, Weissmuller T, Mager A, Eckle T. Nucleotide metabolism and cell-cell interactions. Methods Mol Biol 341: 73-87, 2006.
20. Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 279: 50042-50049, 2004.
21. Engler RL. Harnessing nature's own cardiac defense mechanism with acadesine, an adenosine regulating agent: importance of the endothelium. J Card Surg 9: 482-492, 1994.
22. Feoktistov I, Biaggioni I, Cronstein BN. Adenosine receptors in wound healing, fibrosis and angiogenesis. Handb Exp Pharm: 383-397, 2009.
23. Fernandez JR, Sweet ES, Welsh WJ, Firestein BL. Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine. Bioorg Med Chem 18: 6748-6755, 2010.
24. Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev 161: 27-42, 1998.
25. Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res 316: 1284-1288, 2010.
26. Fredholm BB, Johansson S, Wang YQ. Adenosine and the regulation of metabolism and body temperature. Adv Pharmacol 61: 77-94, 2011.
27. Frye CA, Patrick CW Jr. Isolation and culture of rat microvascular endothelial cells. In Vitro Cell Dev Biol Anim 38: 208-212, 2002.
28. Gessi S, Merighi S, Fazzi D, Stefanelli A, Varani K, Borea PA. Adenosine receptor targeting in health and disease. Expert Opin Investig Drugs 20: 1591-1609, 2011.
29. Giblett ER. ADA and PNP deficiencies: how it all began. Ann NY Acad Sci 451: 1-8, 1985.
30. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflügers Arch 447: 728-734, 2004.
31. Grenz A, Bauerle JD, Dalton JH, Ridyard D, Badulak A, Tak E, McNamee EN, Clambey E, Moldovan R, Reyes G, Klawitter J, Ambler K, Magee K, Christians U, Brodsky KS, Ravid K, Choi DS, Wen J, Lukashev D, Blackburn MR, Osswald H, Coe IR, Nürnberg B, Haase VH, Xia Y, Sitkovsky M, Eltzschig HK. Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest 122: 693-710, 2012.
32. Grenz A, Homann D, Eltzschig HK. Extracellular adenosine: a safety signal that dampens hypoxia-induced inflammation during ischemia. Antioxid Redox Signal 15: 2221-2234, 2011.
33. Grenz A, Zhang H, Eckle T, Mittelbronn M, Wehrmann M, Kohle C, Kloor D, Thompson LF, Osswald H, Eltzschig HK. Protective role of ecto-5=-nucleotidase (CD73) in renal ischemia. J Am Soc Nephrol 18: 833-845, 2007.
34. Grenz A, Zhang H, Hermes M, Eckle T, Klingel K, Huang DY, Muller CE, Robson SC, Osswald H, Eltzschig HK. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 21: 2863-2873, 2007.
35. Guinzberg R, Cortes D, Diaz-Cruz A, Riveros-Rosas H, Villalobos-Molina R, Pina E. Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors. Am J Physiol Endocrinol Metab 290: E940-E951, 2006.
36. Gupta NK, Glantz MD. Isolation and characterization of human liver guanine deaminase. Arch Biochem Biophys 236: 266-276, 1985.
37. Guranowski A, Montgomery JA, Cantoni GL, Chiang PK. Adenosine analogues as substrates and inhibitors of S-adenosylhomocysteine hydrolase. Biochemistry 20: 110-115, 1981.
38. Hashikawa T, Hooker SW, Maj JG, Knott-Craig CJ, Takedachi M, Murakami S, Thompson LF. Regulation of adenosine receptor engagement by ecto-adenosine deaminase. FASEB J 18: 131-133, 2004.
39. Hasko G, Kuhel DG, Nemeth ZH, Mabley JG, Stachlewitz RF, Virag L, Lohinai Z, Southan GJ, Salzman AL, Szabo C. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol 164: 1013-1019, 2000.
40. Hespel P, Richter EA. Role of adenosine in regulation of carbohydrate metabolism in contracting muscle. Adv Exp Med Biol 441: 97-106, 1998.
41. Inoue T, Mi Z, Gillespie DG, Jackson EK. Cyclooxygenase inhibition reveals synergistic action of vasoconstrictors on mesangial cell growth. Eur J Pharmacol 361: 285-291, 1998.
42. Ishikura T, Nakamura H, Sugawara T, Itoh T, Nomura A, Mizuno Y. Inhibition of S-adenosylhomocysteine hydrolase by purine nucleoside analogues. Nucleic Acids Symp Ser: 119-122, 1983.
43. Jackson EK, Dubey RK. Role of the extracellular cAMP-adenosine pathway in renal physiology. Am J Physiol Renal Physiol 281: F597-F612, 2001.
44. Jackson EK, Ren J, Cheng D, Mi Z. Extracellular cAMP-adenosine pathways in the mouse kidney. Am J Physiol Renal Physiol 301: F565-F573, 2011.
45. Jackson EK, Ren J, Mi Z. Extracellular 2=,3=-cAMP is a source of adenosine. J Biol Chem 284: 33097-33106, 2009.
46. Jacobson KA. Introduction to adenosine receptors as therapeutic targets. Handb Exp Pharmacol: 1-24, 2009.
47. Jin M, Yang F, Yang I, Yin Y, Luo JJ, Wang H, Yang XF. Uric acid, hyperuricemia and vascular diseases. Front Biosci 17: 656-669, 2012.
48. Kelly KJ, Plotkin Z, Dagher PC. Guanosine supplementation reduces apoptosis and protects renal function in the setting of ischemic injury. J Clin Invest 108: 1291-1298, 2001.
49. Kim J, Park SI, Ahn C, Kim H, Yim J. Guanine deaminase functions as dihydropterin deaminase in the biosynthesis of aurodrosopterin, a minor red eye pigment of Drosophila. J Biol Chem 284: 23426-23435, 2009.
50. Kloor D, Osswald H. S-Adenosylhomocysteine hydrolase as a target for intracellular adenosine action. Trends Pharmacol Sci 25: 294-297, 2004.
51. Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab 5: 63-84, 2004.
52. Kumar V, Sharma A. Adenosine: an endogenous modulator of innate immune system with therapeutic potential. Eur J Pharmacol 616: 7-15, 2009.
53. Lambe CU, Nelson DJ. Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice. Biochem Pharmacol 31: 535-539, 1982.
54. Lazarowski ER, Sesma JI, Seminario-Vidal L, Kreda SM. Molecular mechanisms of purine and pyrimidine nucleotide release. Adv Pharmacol 61: 221-261, 2011.
55. Lecka J, Bloch-Boguslawska E, Molski S, Komoszynski M. Extracellular purine metabolism in blood vessels (Part II): Activity of ectoenzymes in blood vessels of patients with abdominal aortic aneurysm. Clin Appl Thromb Hemost 16: 650-657, 2010.
56. Linden J. Regulation of leukocyte function by adenosine receptors. Adv Pharmacol 61: 95-114, 2011.
57. Lum CT, Schmidtke JR, Sutherland DE, Najarian JS. Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA). Clin Immunol Immunopathol 10: 258-261, 1978.
58. Lum CT, Sutherland DE, Najarian JS. Inhibition of PHA and NaIO4 mitogenesis by the adenosine deaminase inhibitors erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 2-deoxycoformycin (2-dCF). Clin Immunol Immunopathol 12: 453-459, 1979.
59. Lupidi G, Cristalli G, Marmocchi F, Riva F, Grifantini M. Inhibition of adenosine deaminase from several sources by deaza derivatives of adenosine and EHNA. J Enzym Inhib 1: 67-75, 1985.
60. Mabley JG, Pacher P, Murthy KGK, Williams W, Southan GJ, Salzman AL, Szabo C. The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury. Shock 32: 258-262, 2009.
61. Major PP, Agarwal RP, Kufe DW. Clinical pharmacology of deoxycoformycin. Blood 58: 91-96, 1981.
62. Marshall JM. Roles of adenosine in skeletal muscle during systemic hypoxia. Clin Exp Pharmacol Physiol 29: 843-849, 2002.
63. McKee RW, Parks ME, Dickey A. Influence of iodoacetate on glycolytic intermediates and on respiration in Ehrlich-Lettre ascites carcinoma cells. Arch Biochem Biophys 124: 450-455, 1968.
64. Mohsenin A, Blackburn MR. Adenosine signaling in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 12: 54-59, 2006.
65. Mokkapatti R, Vyas SJ, Romero GG, Mi Z, Inoue T, Dubey RK, Gillespie DG, Stout AK, Jackson EK. Modulation by angiotensin II of isoproterenol-induced cAMP production in preglomerular microvascular smooth muscle cells from normotensive and genetically hypertensive rats. J Pharmacol Exp Ther 287: 223-231, 1998.
66. Mullane K. Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc Res 27: 43-47, 1993.
67. Mustafa SJ, Morrison RR, Teng B, Pelleg A. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharm: 161-188, 2009.
68. Naydenova Z, Rose JB, Coe IR. Inosine and equilibrative nucleoside transporter 2 contribute to hypoxic preconditioning in the murine cardiomyocyte HL-1 cell line. Am J Physiol Heart Circ Physiol 294: H2687-H2692, 2008.
69. Pastor-Anglada M, Errasti-Murugarren E, Aymerich I, Casado FJ. Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling. J Physiol Biochem 63: 97-110, 2007.
70. Pelleg A, Katchanov G, Xu J. Autonomic neural control of cardiac function: modulation by adenosine and adenosine 5=-triphosphate. Am J Cardiol 79: 11-14, 1997.
71. Peng Z, Fernandez P, Wilder T, Yee H, Chiriboga L, Chan ESL, Cronstein BN. Ecto-5=-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis. Nucleosides Nucleotides Nucleic Acids 27: 821-824, 2008.
72. Rathbone M, Pilutti L, Caciagli F, Jiang S. Neurotrophic effects of extracellular guanosine. Nucleosides Nucleotides Nucleic Acids 27: 666-672, 2008.
73. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 161: 95-109, 1998.
74. Riksen NP, Rongen GA, Blom HJ, Russel FGM, Boers GHJ, Smits P. Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc Res 59: 271-276, 2003.
75. Sager G. Cyclic GMP transporters. Neurochem Int 45: 865-873, 2004.
76. Sanchez-Lozada LG, Nakagawa T, Kang DH, Feig DI, Franco M, Johnson RJ, Herrera-Acosta J. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens 15: 30-33, 2006.
77. Schmidt AP, Bohmer AE, Schallenberger C, Antunes C, Tavares RG, Wofchuk ST, Elisabetsky E, Souza DO. Mechanisms involved in the antinociception induced by systemic administration of guanosine in mice. Br J Pharmacol 159: 1247-1263, 2010.
78. Sebastiao AM, Ribeiro JA. Adenosine receptors and the central nervous system. Handb Exp Pharm: 471-534, 2009.
79. Seegmiller JE. Overview of possible relation of defects in purine metabolism to immune deficiency. Ann NY Acad Sci 451: 9-19, 1985.
80. Siaw MF, Mitchell BS, Koller CA, Coleman MS, Hutton JJ. ATP depletion as a consequence of adenosine deaminase inhibition in man. Proc Natl Acad Sci USA 77: 6157-6161, 1980.
81. Sinclair CJ, Powell AE, Xiong W, LaRiviere CG, Baldwin SA, Cass CE, Young JD, Parkinson FE. Nucleoside transporter subtype expression: effects on potency of adenosine kinase inhibitors. Br J Pharmacol 134: 1037-1044, 2001.
82. Souza LF, Horn AP, Gelain DP, Jardim FR, Lenz G, Bernard EA. Extracellular inosine modulates ERK 1/2 and p38 phosphorylation in cultured Sertoli cells: possible participation in TNF-alpha modulation of ERK 1/2. Life Sci 77: 3117-3126, 2005.
83. Stoeckler JD, Cambor C, Kuhns V, Chu SH, Parks RE Jr. Inhibitors of purine nucleoside phosphorylase, C(8) and C(5=) substitutions. Biochem Pharmacol 31: 163-171, 1982.
84. Tedde A, Balis ME, Ikehara S, Pahwa R, Good RA, Trotta PP. Animal model for immune dysfunction associated with adenosine deaminase deficiency. Proc Natl Acad Sci USA 77: 4899-4903, 1980.
85. Thauerer B, zur Nedden S, Baier-Bitterlich G. Purine nucleosides: endogenous neuroprotectants in hypoxic brain. J Neurochem 121: 329-342, 2012.
86. Traversa U, Bombi G, Camaioni E, Macchiarulo A, Costantino G, Palmieri C, Caciagli F, Pellicciari R. Rat brain guanosine binding site. Biological studies and pseudo-receptor construction. Bioorg Med Chem 11: 5417-5425, 2003.
87. Trincavelli ML, Daniele S, Martini C. Adenosine receptors: what we know and what we are learning. Curr Top Med Chem 10: 860-877, 2010.
88. Ugarkar BG, Castellino AJ, DaRe JS, Ramirez-Weinhouse M, Kopcho JJ, Rosengren S, Erion MD. Adenosine kinase inhibitors. 3. Synthesis, SAR, and antiinflammatory activity of a series of L-lyxofuranosyl nucleosides. J Med Chem 46: 4750-4760, 2003.
89. Ugarkar BG, DaRe JM, Kopcho JJ, Browne CE 3rd, Schanzer JM, Wiesner JB, Erion MD. Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues. J Med Chem 43: 2883-2893, 2000.
90. Valen G, Owall A, Takeshima S, Goiny M, Ungerstedt U, Vaage J. Metabolic changes induced by ischemia and cardioplegia: a study employing cardiac microdialysis in pigs. Eur J Cardiothorac Surg 25: 69-75, 2004.
91. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 86: 901-940, 2006.
92. Valls MD, Cronstein BN, Montesinos MC. Adenosine receptor agonists for promotion of dermal wound healing. Biochem Pharmacol 77: 1117-1124, 2009.
93. Vass G, Horvath I. Adenosine and adenosine receptors in the pathomechanism and treatment of respiratory diseases. Curr Med Chem 15: 917-922, 2008.
94. Westfall DP, Shinozuka K, Forsyth KM, Bjur RA. Presynaptic purine receptors. Ann NY Acad Sci 604: 130-135, 1990.
95. Yao SY, Ng AM, Muzyka WR, Griffiths M, Cass CE, Baldwin SA, Young JD. Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. J Biol Chem 272: 28423-28430, 1997.
96. Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD. Transport of antiviral 3=-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol 18: 161-167, 2001.
97. Young JD, Yao SYM, Sun L, Cass CE, Baldwin SA. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 38: 995-1021, 2008.
98. Yu W, Robson SC, Hill WG. Expression and distribution of ectonucleotidases in mouse urinary bladder. PLos One 6: e18704, 2011.
99. Yu W, Zacharia LC, Jackson EK, Apodaca G. Adenosine receptor expression and function in bladder uroepithelium. Am J Physiol Cell Physiol 291: C254-C265, 2006.
100. Zimmermann H. 5=-Nucleotidase: molecular structure and functional aspects. Biochem J 285: 345-365, 1992.